Neutral impactIPO
Dhoot Transmission or Molbio: Which IPO should investors invest in?
Business Standard 1 hr ago·11 Aug 2026, 4:29 am
Investors are currently deciding between two upcoming initial public offerings (IPOs): Dhoot Transmission and Molbio Diagnostics. Dhoot Transmission is a non-banking financial company (NBFC) focused on financing telecom towers and related infrastructure. Molbio Diagnostics is a healthcare company specializing in molecular diagnostics, particularly for infectious diseases. Both companies are looking to raise capital to fund their growth and expansion plans.
The choice between these two IPOs depends on an investor's risk appetite and sector preference. Dhoot Transmission operates in the infrastructure and telecom sector, which is considered stable but potentially sensitive to interest rate changes. Molbio Diagnostics is in the healthcare sector, which is generally considered defensive and less cyclical. Investors should evaluate their own financial goals and risk tolerance before making a decision.
Investors should closely monitor the price band, subscription status, and market sentiment leading up to the listing dates. It is also important to review the company's financials, business model, and future growth prospects. The performance of the broader market and sector-specific trends will also play a crucial role in determining the success of these IPOs.
Key takeaways
- Category: IPO.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. Use the price and stock snapshot to gauge how the market is responding.
